Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Susan Vissers Lisa, CFA, as Senior Director of Investor Relations and Corporate Development. Ms. Lisa brings more than 20 years of capital markets and healthcare experience, as well as an extensive background in medical technology, financial analysis, and sales and marketing management.
“We are extremely pleased to have Susie Lisa on board during an exciting time of continued growth and opportunity for the Company,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “With a unique background across financial markets, the medical technology sector, and healthcare investors, Susie is well positioned to help Abiomed continue to grow shareholder value as we execute our plan to recover hearts with cost-effective patient outcomes.”
Prior to joining Abiomed, Ms. Lisa was a Managing Director at Bank of America Merrill Lynch. During her 12 year tenure, she was head of Americas Specialist Sales from 2009 to 2011, managing a team of 20+ dedicated sector sales specialists across all sectors of the S&P, while also providing dedicated healthcare sales coverage to major institutional investor clients. In her equity research sales role from 2001 to 2011, Ms. Lisa helped market Bank of America Merrill Lynch’s healthcare equity research and capital markets transactions to some of the most sophisticated healthcare investors in the U.S. and Europe, also working closely with colleagues in trading, derivatives, capital markets, and investment banking to help best position healthcare corporations with investors and drive strong investment returns.
Prior to her sales role, Ms. Lisa spent four years as a medical technology research analyst, both at Merrill Lynch and Cowen & Co. She began her career at J.P. Morgan in a variety of roles, including healthcare investment banking, convertible sales/trading, and internal management consulting.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts